Phase II trial of low dose lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (Rev-Lite) in patients at high risk for myelosuppression

Trial Profile

Phase II trial of low dose lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (Rev-Lite) in patients at high risk for myelosuppression

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RevLite
  • Most Recent Events

    • 07 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results of matched comparison between RevLite and other two phase III trials ( MM009 and MM010) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Aug 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top